ArticleFrontiers in aging neuroscience2026
Plasma α-synuclein and QSM-derived susceptibility in Parkinson's disease: associations with clinical features.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathological interplay between α-synuclein aggregation and iron dysregulation is central to the neurodegenerative process in Parkinson's disease (PD). Quantitative susceptibility mapping (QSM) allows Objective: To evaluate plasma α-synuclein as a diagnostic biomarker (against controls) and to explore whether regional brain iron deposition, measured by QSM, correlates with clinical features and plasma α-synuclein within the PD group. Methods: Fifty-two PD patients and sixty-two age- and sex-matched healthy controls were enrolled. Plasma α-synuclein concentrations were quantified by ELISA. Magnetic susceptibility values of seven deep gray-matter nuclei were obtained using QSM reconstructed from a multi-echo gradient-echo sequence on a 3.0 T MRI scanner. Motor and non-motor symptoms were assessed using MDS-UPDRS-III, H-Y staging, MoCA, MMSE, HAMD, and HAMA scales. Results: Plasma α-synuclein levels were significantly higher in PD than controls [median 54.9 (46.9-60.6) vs. 28.7 (24.4-33.7) pg/μL, Conclusion: Elevated plasma α-synuclein provides a highly discriminative diagnostic biomarker for PD, while regional iron accumulation measured by QSM-derived magnetic susceptibility exhibited nominal associations with clinical and cognitive measures, although these relationships did not remain significant after age adjustment and correction for multiple comparisons. The absence of a direct association between peripheral α-synuclein levels and regional brain iron burden suggests that these biomarkers may reflect partially independent pathological processes in Parkinson's disease. Future longitudinal studies are warranted to clarify the temporal dynamics and potential complementary roles of these biomarkers in disease characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.